natgillin/translations-raw huggingface dataset:
The device 1 operates as follows by implementing the following stages, the mixture of extruded PMMA (and/or ABS) contaminated with crosslinked PMMA being initially 
Uređaj 1 radi kao što slijedi i to provođenjem sljedećih stupnjeva, pri čemu se prvo mješavina ekstrudiranog PMMA (iii ABS) koji je kontaminiran s umreženim PMMA
On the one hand, in this manner, it is possible to adapt the color of the adhesive to the color of the employed pieces of wood respectively to the color of the pieces of material being different from wood. 
S druge strane, na taj način se može prihvatiti boja ljepila uz boju koju imaju komadi od drva, odnosno uz boju koju imaju komadi od materijala koji je
having a heavy chain comprising a polypeptide having the sequence provided in SEQ ID NO:145 or 392, and a light chain comprising a polypeptide having the sequence provided in SEQ ID NO: 141; 
Protutijelo za vezanje sklerostina iz patentnog zahtjeva 1, naznačeno time, da ima teške lance SEQ ID NO: 145 ili 392 i lake lance SEQ ID NO: 141.
In said drawings, reference numeral 1 globally denotes an inhaler device of at least one powdered substance contained in a capsule 2 of the type having an operculum formed of two parts. 
HR P20161226 T1 PATENTNI ZAHTJEVI Aparat za inhalaciju (1) praškaste konzistencije sadržane u kapsuli (2) tipa koji ima poklopac sastavljen iz dva dijela koji obuhvaća:
Enough SDS has to be added to re-solubilise precipitated IL-2 into a substantially monomeric soluble form, and then it must be removed (but not completely) to give the desired microaggregates. 
PROLEUKINTM, Mora se dodati dovoljno SDS da se ponovno otopi istaloženi IL-2 u u biti monomerni topivi oblik, a zatim se mora odstraniti (ali ne potpuno) da dade željene mikroagregate.
The method of item 8, wherein the tofogliflozin comprises a crystal form I, a crystal form II, an amorphous form, or a mixture thereof. 
Postupak prema zahtjevu 8, naznačen time što tofogliflozin obuhvaća kristalni oblik I, kristalni oblik II, amorfni oblik, ili njihovu smjesu.
The following examples illustrate the invention in greater detail. 
Sljedeći primjeri ilustriraju izum detaljnije.
The piezoelectric power supply converter as claimed in claim 15, wherein said equivalent circuit of said piezoelectric-capacitor includes said equivalent resistor R, said equivalent inductor L, said equivalent capacitor Ca, and a static capacitor Cb, and said equivalent capacitance of said piezoelectric oscillator is expressed as: EPMATHMARKEREP wherein, w is an operation frequency (rad/s). 
Piezoelektrični pretvornik napajanja prema zahtjevu 9, naznačen time da ekvivalentni krug navedenog piezoelektričnog kondenzatora (13) uključuje ekvivalentni otpornik R, ekvivalentni induktor L, i ekvivalentni kondenzator Ca, te statički kondenzator Cb, a navedeni ekvivalentni kapacitet navedenog piezoelektričnog kondenzatora izražava se kao: [image] pri čemu w je radna frekvencija (rad/s).
An expression vector comprising the nucleic acid of claim 1 . 
Vektor ekspresije koji sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 5.
The resulting solution was treated dropwise with a solution of 4-iodobenzyl bromide (2.97 g, 10.0 mmol) in tetrahydrofuran (4 mL) and then warmed to room temperature. 
Dobivenu otopinu obradi se ukapavanjem otopine 4-jodbenzil-bromida (2,97 g, 10,0 mmol) u tetrahidrofuranu (4 ml), te zagrije na sobnu temperaturu.
In an embodiment of the invention the fumaric acid ester is micronized to obtain a particle size, wherein at least 90 % of the particles have a particle size of at most 50 µm, such as at most 30 µm, such as at most 10 µm, prior to step a) above. 
Postupak prema zahtjevu 18, naznačen time, da se kristali estera fumarne kiseline prosijavaju ili melju tako da 90% čestica imaju veličinu čestice u rasponu od 5 do 1000um.
The subject invention also provides a pharmaceutical tablet formulation (Formulation B), comprising per 600 mg tablet the following ingredients: 
Farmaceutska formulacija tablete, naznačena time, da sadrži po 400 mg tableti slijedeće sastojke:
The recombinant anti-a4 antibody molecule, or a4-binding fragment thereof, for use according to claim 5, wherein the patient has an acute disorder, a spinal cord injury or traumatic brain injury. 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, za uporabu prema zahtjevu 3, naznačena time, da pacijent ima upalni poremećaj, multiplu sklerozu, astmu, reumatoidni artritis, dijabetes, optički neuritis, Crohnovu bolest, akutni poremećaj, ozljedu kralježnice ili traumatsku ozljedu mozga.
As can be clearly seen, the level of adverse events associated with the free base form of the compound was much lower when the compound was enterically coated. 
Kao što se može jasno vidjeti, razina štetnih događaja povezanih s oblikom slobodne baze spoja je bila puno niža kad je spoj bio enterički obložen.
The extended release tablet formulation according to any of the previous claims, wherein the contained amount of pramipexole or pharmaceutically acceptable salt thereof is sufficient to provide a daily dose administered at one time. 
Formulacija tablete produljenog oslobađanja u skladu s bilo kojim prethodnim zahtjevom, naznačena time, da je sadržana količina pramipeksola ili njegove farmaceutski prihvatljive soli dovoljna da osigura dnevnu dozu primjenjenu odjednom.
is a hydrogen atom, a C1-6 alkyl group, a C3-8 cycloalkyl group, an amino group, or a C1-6 alkylamino group, and the group of substituents, Rc, consists of a halogen atom and a hydroxy group. 
je vodikov atom, skupina C1-6 alkil, skupina C3-8 cikloalkil, amino skupina, ili skupina C1-6 alkilamino, i skupina supstituenata, Rc, sadrži halogeni atom i hidroksi skupinu.
reacting a compound of Formula 2, or a salt thereof, with an acid and water to yield the compound of Formula 1 or a salt thereof; and 
g, s enzimom, kako bi se dobilo spoj Formule 3, ili njegovu sol, i spoj Formule 5 R!
(4-fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl)methanamine hydrochloride Intermediate 62 was prepared according to procedure for intermediate 35. 
(4-fluoro-2-(5-metil-1H-1,2,4-triazol-1-il)fenil)melanamin hidroklorid: Intermedijer 62 je pripremljen prema postupku za Intermedijer 35.
The compound of claim 2, wherein Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus is a free terminus. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Aaa aminokiselinski ostatak, kojeg se bira između Thr i Ser; gdje je C-kraj slobodni kraj.
A dressing according to claim 8, wherein the gelling agent is in the form of a powder or granule or sheet. 
Obloga u skladu s patentnim zahtjevom 8, naznačena time, da je sredstvo za želiranje u obliku praha, granula ili lista.
Furthermore, it is preferred according to the present invention that the first carrier frequency is a licensed frequency assigned to be used by the telecommunications network. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je prva noseća frekvencija (110) licencirana frekvencija određena za korištenje u telekomunikacijskoj mreži (10).
The ratio of the diameters of the first rotor to the second rotor typically is from 1.1:1 to 1.5:1 and from the second to the third rotors typically is from 1:1 to 1.3:1, preferably around 1:1. In particular, it is often preferred that the second, third and any subsequent rotors should have substantially the same diameter. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, pri čemu su osi prvog i drugog rotora raspoređene tako da linija koja se vuče od osi prvog rotora do osi drugog rotora pravi kut od 0 do 20", ispod vodoravne.
the molecular entity comprising a protein having a peptide affinity tag attached to a component of the protein layer; the molecular entity comprising a protein, and both of a component of the protein layer and the molecular entity having respective affinity tags attached to each other; or 
HR P20110872 TI molekularni entitet koji sadrži protein s peptidnom afinitetnom oznakom pričvršćenom na komponentu proteinskog sloja; molekularni entitet sadrži protein, a komponenta proteinskog sloja i molekularni entitet imaju odgovarajuće afinitetne oznake spojene jedna na drugu; ili molekularni entiteti genetičkim su putem spojeni unutar komponente proteinskog sloja,
One aspect of the present invention is that the pipe connections of the invention will tend to have a characteristic increased radial interlock at the box face region due to an increased thread height in that region of the connection. 
(21) klina i naznačen time da element klina ima karakteristično povećano radijalno zaključavanje u prednjem dijelu (21) klina zbog povećane visine navoja (h5) u tom području spoja. 4.
R2a is hydrogen, C4-6cycloalkyl or phenyl, said C4-6cycloalkyl and phenyl can optionally be substituted by 1, 2 or 3 substituents independently selected from the group consisting of: halogen, cyano, hydroxyl, carboxyl, amino, C1-4alkyl and haloC1-4alkyl; 
R* je vodik, Cagcikloalkil ili fenil, spomenuti Cagcikloalkil i fenil mogu izborno biti supstituirani s 1, 21li 3 supstituenta nezavisno odabranih iz skupine koja se sastoji od: halogena, cijano, hidroksila, karboksila, amino, C,aalkila i haloC,,alkila;
Said object is solved by a process for the manufacture of a veneer having the features of independent claim 1 and by the device for carrying out said process according to claim 35. 
Navedeni cilj se rješava pomoću postupka za proizvodnju furnira koji ima karakteristike neovisnog patentnog zahtjeva 1 i pomoću uređaja za izvođenje navedenog postupka koji je u skladu s patentnim zahtjevom 29.
The concentrations selected were based on the results of a non-GLP solubility/miscibility/range-finding cytotoxicity (ATP) assay with the compound of interest. 
Izabrane koncentracije se temelje na rezultatima (ATP) testa ne- GLP otopljenosti/miješanja/nalaženja opsega citotoksičnosti sa spojem od značaja.
The biomimetic compound of claim 18 or the composition of claim 17 for use in a method of modulating an immune response or treating an autoimmune or inflammatory disease in a subject, the method comprising administering to the subject an effective amount of the biomimetic compound. 
Spoj biomimetika prema zahtjevu 4, naznačen time, da se upotrebljava u postupku prilagođavanja imunološkog odgovora ili liječenja upalne bolesti kod pojedinca, pri čemu taj postupak obuhvaća davanje pojedincu učinkovite količine spoja biomimetika.
A method of interfering with the accumulation of protein or peptide aggregates in a cell, or preventing, slowing, reversing, or inhibiting protein or peptide aggregation in a cell, comprising contacting the cell with an effective amount of at least one compound or pharmaceutically acceptable salt according to any one of claims 1 to 12 or a pharmaceutical composition according to claim 13 or 14, wherein the contacting is in vitro or ex vivo. 
Metoda posredovanja sa akumulacijom proteinskih ili peptidnih agregata u stanici, ili spriječavanje, usporavanje, preusmjeravanje, ili inhibiranje proteinske ili peptidne agregacije u stanici, koja obuhvaća kontaktiranje stanice sa efikasnom količinom najmanje jednog spoja ili farmaceutski prihvatljive soli u skladu sa bilo kojim od patentnih zahtjeva 1 do 3 ili farmaceutske kompozicije u skladu sa patentnim zahtjevom 4, gdje je kontaktiranje in vitro ili ex vivo.
A combination of a first agent that inhibits hedgehog signaling pathway wherein said first agent is cyclopamine or forskolin and a second agent that inhibits BCR-ABL wherein said second agent is selected from the group consisting of 
Kombinacija, naznačena time, da je sastavljena od prvog sredstva koje inhibira signalni put Hedgehog, pri čemu je to prvo sredstvo ciklopamin ili forskolin, te od drugog sredstva koje inhibira BCR-ABL, pri čemu je to drugo sredstvo odabrano iz skupine koja se sastoji od:
Dehydration of reduced Tetrabenazine 
Dehidriranje reduciranog tetrabenazina
The composition for use of claim 1, wherein the gastroesophageal reflux disease is nonerosive reflux disease (NERD) or erosive esophagitis (EE). 
Stabilni oralni farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-12, naznačen time da je upala jednjaka povezana s Baretovim jednjakom, gastroezofagealnom refluksnom bolesti (GERB), neerozivnom refluksnom bolesti (NERB), ili erozivnim ezofagitisom.
A composition comprising at least one compound as defined in claim 1 or the compound and at least one therapeutic agent chosen from anagrelide, hydroxyurea, P32, busulphan, aspirin, clopidogrel, a-interferon ticlopidine and dipyridamole. 
Kompozicija koja sadrži najmanje jednan spoj definiran Zahtjevom 1 ili spoj [image] i najmanje jedan terapeutski agens koji se bira između anagrelida, hidroksiuree, P32, bisulfana, aspirina, klopidogrela, -interferon tiklopidina i dipiridamola.
A. dispensing line 10, which pushes in the spring valve 9, is connected to a tap head 13 by means of which a shutoff valve, which is not shown in more detail, at the end of the dispensing line 10 can be opened and closed via a tap handle 14. 
Razdjelni vod 10, koja utiskuje u ventila na oprugu 9, je spojen na glavu za istjecanje 13, na taj način da ventil za zatvaranje, koji nije detaljnije prikazan, na kraju razdjelnog voda 10 može biti otvoren i zatvoren pomoću ručke za istakanje 14.
Otitis media Neurological diseases, which coincide with inflammatory, allergic and/or proliferative processes: 
(x1i) neuroloških bolesti, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
The method of clause 41, wherein the disorders and diseases are selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. 
Farmaceutska kompozicija prema patentnom zahtjevu 5, naznačena time što je poremećaj ili bolest izabran/izabrana iz grupe koju čine poremećaji i bolesti srca, poremećaji i bolesti skeletnih mišića, kognitivni poremećaji i bolesti, maligna hipertermija, dijabetes i sindrom iznenadne smrti novorođenčeta.
The reaction became a clear solution and strongly exothermic. 
Reakcijska smjesa postaje bistra, jako egzotermna otopina.
Because of the following two observations: 
Datum objave europske prijave patenta:
represents an aryl or heterocyclyl group wherein said aryl and heterocyclyl groups may be optionally substituted by one or more Rb groups; 
predstavlja aril ili heterociklil grupu, pri čemu spomenute aril i heterociklil grupe mogu biti opcionalno supstituirane sa jednom ili više Rb grupa;
A transdermal delivery device comprising: a polymer matrix layer comprising an opioid agonist and microspheres of opioid antagonist, wherein the microspheres are embedded within the matrix and the antagonist is non-releasable when the transdermal delivery device is applied topically and intact to a skin of a human patient. 
Sredstvo za transdermalno davanje koje sadrži: sloj koji sadrži lijek gdje navedeni sloj sadrži učinkovitu količinu opioidnog agonista i veći broj mikrosfera dispergiranih u sloju koji sadrži lijek, mikrosfere koje sadrže opioidni antagonist i gdje su mikrosfere srednje veličine od 1 do 300 um u promjeru.
to form a composition; shaping the composition to form an extended release matrix formulation; and curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 1 minute. 
(b) oblikovanje sastava kako bi se dobila formulacija matrice s produljenim otpuštanjem; i (c) stvrdnjavanje navedene formulacije matrice s produljenim otpuštanjem koje sadrži barem korak stvrdnjavanja u kojem se formulacija matrice s produljenim otpuštanjem podvrgava temperaturi koja je barem temperatura omekšavanja navedenog polietilen oksida u periodu od barem oko 1 minute.
In various embodiments, this psychiatric drug may be chosen from an antidepressant, an anxiolytic, a CNS stimulant, a neuroleptic, an opioid, nicotine, or another NMDA antagonist. 
D-metadon za uporabu prema zahtjevu 4, naznačen time što psihijatrijski lijek je antidepresiv, anksiolitik, stimulans SŽS, neuroleptik, opioid, nikotin, ili drugi antagonist NMDA.
The pharmaceutical composition of any one of claims 1-5, wherein the oligosaccharide chain comprises at least one branch having the structure NeuNAc2a3GalB4GlcNAcB2Mana6. 
Glikozilirani humani SAP polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da oligosaharidni lanac sadržava najmanje jednu granu koja ima strukturu NeuNAc2a3Gal4GlcNAc2Mana6
The dry powder inhaler discharges the contents of all of the containers disposed therein, and thereby provides the user with a therapeutically effective amount of the aerosol powder. 
Suhi sastav praškastog aerosola za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da se suhi sastav praškastog aerosola formulira za davanje pacijentu uporabom inhalatora za suhi prašak.
Suitable bitter substances are preferably aromatic oils, preferably peppermint oil, eucalyptus oil, bitter almond oil, menthol, fruit aroma substances, preferably aroma substances from lemons, oranges, limes, grapefruit or mixtures thereof, and/or denatonium benzoate. 
Kao gorke tvari prvenstveno su prikladna miomirisna ulja, prije svega ulje paprene metvice, eukaliptusovo ulje, ulje gorkih badema, mentol, miomirisne tvari plodova, prvenstveno miomirisne tvari četruna, naranči, limuna, grejpfruta ili njihovih smjesa, i/ili denatonijev- benzoat (Bitrex?).
A method according to claim 10 wherein the patient is suffering from a pre-existing heart condition or condition that would be aggravated by tachycardia. 
Uporaba sukladno bilo kojem od patentnih zahtjeva 11, 19 120, naznačena time, da se koristi za liječenje bolesnika koji pate od prijašnjeg srčanog stanja ili stanja koje može biti pogoršano tahikardijom.
A compound of formula (XII): wherein: 
Spoj s formulom (XII): [image] naznačen time da:
Q represents aryl substituted by 0-4 substituents V or a 5- or 6-membered heteroaromatic substituted by 0-4 substituents V, where 
Q predstavlja aril supstituiran sa O - 4 supstituenata V ili 5- ili 6-člani heteroaromatski spoj supstituiran sa 0 - 4 supstituenata V, gdje
The method according to claim 1, wherein the disease or disorder is liver cancer. 
Spoj ili sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak jetre.
a nucleotide sequence hybridizing under stringent conditions with the sequence from (a) or (b). 
(c) nukleotidne sekvence koja hibridizira pod strogim uvjetima sa sekvencom pod (a) ili (b).
A solution of sodium hydroxide (3.7 g) in water (10 ml) was added to the stirring reaction mixture, followed by an aqueous solution of hydrogen peroxide (50%, ca. 7 ml) and the two-phase mixture formed was stirred at reflux for one hour. 
U miješanu reakcijsku smjesu se doda otopina natrij hidroksida (3.7 g) u vodi (10 ml) i nakon toga se doda 1 vodena otopina vodikovog peroksida (50%, oko 7 ml) te se formirana dvo-fazna smjesa miješa uz refluks tijekom jednog sata.
In some embodiments, provided are 19-mer double-stranded nucleic acid molecules wherein the sense strand is SEQ ID NO:98 and includes 2′-5′-ribonucleotides in positions at the 3′-terminus; a non-nucleotide moiety covalently attached at the 3′-terminus; and a cap moiety covalently attached at the 5′-terminus; and the antisense strand is SEQ ID NO:165 and includes 2′OMe modified ribonucleotides; a 2′-5′-ribonucleotide in at least one of positions 5, 6 or 7; and a non-nucleotide moiety covalently attached at the 3′-terminus. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što smisleni lanac sadrži SEQ ID NO:98, a protusmisleni lanac sadrži SEQ ID NO:165; gdje smisleni lanac dodatno sadrži 2'-5'- ribonukleotide na položajima na ili blizu 3'-kraja; nenukleotidni ostatak kovalentno vezan na 3'-kraju; i ostatak koji vrši ulogu kape kovalentno vezan na 5'-kraju; i gdje protusmisleni lanac dodatno sadrži 2'-O-metilom modificirani ribonukleotid; 2'-5'-ribonukleotid na najmanje jednom od položaja 5, 6 ili 7; i nenukleotidni ostatak kovalentno vezan na 3'-kraju.
The panel according to claim 1, further comprising photovoltaic cells, wherein the upper plateau is covered with the photovoltaic cells. 
Ploča prema bilo kojem od prethodnih zahtjeva, naznačena time što je gornja ploha (7, 7) prekrivena s fotonaponskim ćelijama.
In a preferred embodiment, before, during, or after step c), but before step d), at least one earth alkali oxide and/or hydroxide, preferably lime and/or burnt dolomite is added to the aqueous suspension of step b), wherein lime in the context of the present invention comprises calcium oxide and calcium hydroxide. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je prije, tijekom, ili nakon koraka c), ali prije koraka d), najmanje jedan zemljo-alkalni oksid i/ili hidroksid, poželjno vapno i/ili žareni dolomit dodan u vodenu suspenziju iz koraka b).
The invention further comprises providing a transport line for liquid feed from the liquid/gas separation section of the urea plant to said evaporation chamber and providing a gas flow-line from the liquid/gas separation section of the urea plant to a condensation system. The condensation system comprises a liquid outlet in fluid communication with the indirect heating chamber. 
metoda također uključuje liniju za transport tekućine od dijela za odvajanje tekućine/plina u sklopu pogona za proizvodnju uree do navedene evaporacijske komore; liniju za protok plina iz dijela za odvajanje tekućine/plina u sklopu pogona za proizvodnju melamina do kondenzacijskog sustava, s tim da isti kondenzacijski sustav uključuje ulazni otvor povezan tekućinom s komorom za neizravnu izmjenu topline;
The compound according to Claim 1 or a pharmacologically acceptable salt thereof, which is 6-(1-((6-Cyclopropyl-3-ethoxy-2,4'-difluorobiphenyl-4-yl)methyl)piperidin-4-yl)-2-ethyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridine-3-carboxylic acid or a pharmacologically acceptable salt thereof. 
Spoj prema zahtjevu 1 ili njegova farmakološki prihvatljiva sol, naznačen/a time, da je to 6-(1-((6-ciklopropil-3etoksi-2,4"-difluorobifenil-4-il)metil)piperidin-4-11)-2-etil-5-okso-5,6,7,8-tetrahidro-1,6-naftiridin-3-karboksilna kiselina ili njezina farmakološki prihvatljiva sol.
Where the promoter is “native” or “analogous” to the plant host, it is intended that the promoter is found in the native plant into which the promoter is introduced. 
Molekula nukleinske kiseline iz patentnog zahtjeva 1, naznačena time, da je navedeni nukleotidni odsječak funkcionalno povezan s promotorom koji može usmjeravati eksprimiranje kodirajućeg odsječka u stanici biljke.
An assembly according to any one of the preceding claims, wherein the drive means is arranged to accelerate the pressing head and the support member in the first direction to a speed which substantially matches a speed of the moving board. 
Sklop prema bilo kojem od prethodnih zahtjeva, naznačen time da su pogonska sredstva (20) postavljena tako da ubrzaju pritisnu glavu (16) i potporni element (17) u prvom smjeru na brzinu koja uglavnom odgovara brzini ploče (100) koja se kreće.
The pharmaceutical composition in form of emulsion or microemulsion for use according to claim 1, wherein said composition has a viscosity below about 0,15 Pas (150 cP), preferably below about 0,1 Pas (100 cP), more preferably below about 0,05 Pa·s (50 cP), much more preferably below about 0,02 Pas (20 cP) and wherein said viscosity is preferably measured at about 25°C, at about 30°C and/or at about 37°C. 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 1, gdje taj pripravak ima viskoznost nižu od oko 0,15 Pa:s (150 cP), poželjno nižu od oko 0,1 Pa:s (100 cP), poželjnije nižu od oko 0,05 Pa:s (50 cP), još poželjnije nižu od oko 0,02 Pa:s (20 cP).
The formulation of claim 1 or 2, wherein the polyalcohol is propylene glycol, which is preferably present in an amount of 20.0%wt. 
Formulacija prema zahtjevu 1 ili 2, naznačena time, da navedeni polialkohol je propilen glikol, koji je poželjno prisutan u količini od 20.0% tež.